Australia-based Cell Therapies and Japan's Teijin Limited have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific region.
This partnership will combine Cell Therapies’ long-standing expertise as Australia’s leading CGT CDMO with Teijin’s strong manufacturing capabilities in CGT and regenerative medicine via their group companies Teijin Regenet Co. and Japan Tissue Engineering Co.（J-TEC）in Japan.
The collaboration aims to streamline access to regional markets by enabling cross-border clinical trial and commercial supply, knowledge exchange, and regulatory alignment to support innovative CGT programs.
Through this collaboration, the companies intend to:
